{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Rocket Pharmaceuticals, Inc. technically bullish or bearish?
As of May 6, 2025, Rocket Pharmaceuticals, Inc. is in a bearish trend with strong weakness indicated by bearish MACD signals, Bollinger Bands, and moving averages, along with underperformance against the S&P 500.
Who are in the management team of Rocket Pharmaceuticals, Inc.?
As of March 2022, the management team of Rocket Pharmaceuticals, Inc. includes Dr. Roderick Wong (Chairman), Dr. Gaurav Shah (CEO), and several independent directors: Mr. David Southwell, Dr. Elisabeth Bjork, Mr. Carsten Boess, Mr. Pedro Granadillo, and Dr. Gotham Makker. They oversee the company's strategic direction and operations.
What does Rocket Pharmaceuticals, Inc. do?
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases, with a market cap of approximately $293 million and a net profit of -$61 million as of March 2025. The company has no dividend yield and negative financial metrics, indicating it is currently loss-making.
How big is Rocket Pharmaceuticals, Inc.?
As of Jun 18, Rocket Pharmaceuticals, Inc. has a market capitalization of 293.05 million and reported net sales of 0.00 million with a net profit of -258.03 million over the latest four quarters. Shareholder's funds are 463.23 million, and total assets amount to 527.70 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
